QBRELIS Drug Patent Profile
✉ Email this page to a colleague
When do Qbrelis patents expire, and what generic alternatives are available?
Qbrelis is a drug marketed by Azurity and is included in one NDA. There are eleven patents protecting this drug and one Paragraph IV challenge.
This drug has ten patent family members in eight countries.
The generic ingredient in QBRELIS is lisinopril. There are twenty-one drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the lisinopril profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Qbrelis
A generic version of QBRELIS was approved as lisinopril by ASCENT PHARMS INC on July 1st, 2002.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for QBRELIS?
- What are the global sales for QBRELIS?
- What is Average Wholesale Price for QBRELIS?
Summary for QBRELIS
International Patents: | 10 |
US Patents: | 11 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 82 |
Clinical Trials: | 2 |
Drug Prices: | Drug price information for QBRELIS |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for QBRELIS |
What excipients (inactive ingredients) are in QBRELIS? | QBRELIS excipients list |
DailyMed Link: | QBRELIS at DailyMed |


Recent Clinical Trials for QBRELIS
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Cancer Institute (NCI) | Phase 2 |
St. Jude Children's Research Hospital | Phase 2 |
Mayo Clinic | Phase 2 |
Pharmacology for QBRELIS
Drug Class | Angiotensin Converting Enzyme Inhibitor |
Mechanism of Action | Angiotensin-converting Enzyme Inhibitors |
Paragraph IV (Patent) Challenges for QBRELIS
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
QBRELIS | Oral Solution | lisinopril | 1 mg/mL | 208401 | 1 | 2019-10-24 |
US Patents and Regulatory Information for QBRELIS
QBRELIS is protected by twenty-nine US patents.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Azurity | QBRELIS | lisinopril | SOLUTION;ORAL | 208401-001 | Jul 29, 2016 | RX | Yes | Yes | 12,186,360 | ⤷ Try for Free | Y | ⤷ Try for Free | |||
Azurity | QBRELIS | lisinopril | SOLUTION;ORAL | 208401-001 | Jul 29, 2016 | RX | Yes | Yes | 12,128,083 | ⤷ Try for Free | Y | ⤷ Try for Free | |||
Azurity | QBRELIS | lisinopril | SOLUTION;ORAL | 208401-001 | Jul 29, 2016 | RX | Yes | Yes | 9,616,096 | ⤷ Try for Free | ⤷ Try for Free | ||||
Azurity | QBRELIS | lisinopril | SOLUTION;ORAL | 208401-001 | Jul 29, 2016 | RX | Yes | Yes | 11,179,434 | ⤷ Try for Free | Y | ⤷ Try for Free | |||
Azurity | QBRELIS | lisinopril | SOLUTION;ORAL | 208401-001 | Jul 29, 2016 | RX | Yes | Yes | 10,406,199 | ⤷ Try for Free | ⤷ Try for Free | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for QBRELIS
See the table below for patents covering QBRELIS around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Korea | 20180069907 | 리시노프릴 제제 | ⤷ Try for Free |
China | 112972370 | 赖诺普利制剂 (LISINOPRIL FORMULATIONS) | ⤷ Try for Free |
Japan | 2018533583 | リシノプリル製剤 | ⤷ Try for Free |
China | 108472252 | 赖诺普利制剂 (LISINOPRIL FORMULATIONS) | ⤷ Try for Free |
European Patent Office | 3960156 | FORMULATIONS DE LISINOPRIL (LISINOPRIL FORMULATIONS) | ⤷ Try for Free |
>Country | >Patent Number | >Title | >Estimated Expiration |
Market Dynamics and Financial Trajectory for QBRELIS
More… ↓